Acetyl-coenzyme A carboxylase α (ACACA) single-nucleotide polymorphism (SNP) (rs2229416) was significantly associated with hypertriglyceridemia, during exploration of antipsychotic direct effects on lipids. Neuropeptide Y (NPY) gene (rs1468271) and ACACB gene (rs2241220) SNPs were significantly associated with severe hypercholesterolemia. In the same sample (173 patients on olanzapine, quetiapine, chlorpromazine or mirtazapine [increasing the risk of hyperlipidemia] and 184 controls taking other antipsychotics), three (rs1266175, rs12453407 and rs9906543) of eight additional ACACA SNPs were significantly associated with hypertriglyceridemia in those taking drugs of interest, but not in controls. Five other ACACA SNPs, three additional NPY SNPs, and seven additional ACACB SNPs were not significant.
|Number of pages||5|
|State||Published - Dec 2009|
Bibliographical noteFunding Information:
No pharmaceutical organizations had any role in the writing of this paper for publication. The original pharmacogenetic study at the University of Kentucky Mental Health Research Center was supported by several sources: a researcher-initiated grant from Roche Molecular Systems, Inc., a NARSAD Independent Investigator Award to Jose de Leon, M.D, and internal resources. Genotyping and statistical analyses were conducted without additional external support. Genotyping of the original SNPs described in prior article were conducted at Genomas, Hartford, CT by Mohan Kocherla.
- Acetyl-coenzyme A carboxylase alpha
- Acetyl-coenzyme A carboxylase beta
- Metabolic syndrome
- Neuropeptide Y
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry